Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 15/20 | 1.00 |
| ▸ | GRM5 | P41594 | 10/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12975664 | 0.90 | GRM1 (0.82) | GRM1GRM5HRH1TMEM97TRPV1 | |
| SCHEMBL2890559 | 0.88 | GRM1 (0.78) | GRM1GRM5HRH1TMEM97TRPV1 | |
| SCHEMBL2885108 | 0.87 | GRM1 (0.77) | GRM1GRM5HRH1TMEM97TRPV1 | |
| SCHEMBL12975637 | 0.86 | GRM1 (0.76) | GRM1GRM5HRH1TMEM97TRPV1 | |
| SCHEMBL2885377 | 0.86 | GRM1 (1.00) | GRM1GRM5HRH1TMEM97TRPV1 | |
| SCHEMBL12975649 | 0.85 | GRM1 (0.74) | GRM1GRM5HRH1TMEM97TRPV1 | |
| SCHEMBL12975656 | 0.84 | GRM1 (0.73) | GRM1GRM5HRH1TMEM97TRPV1 | |
| SCHEMBL2892619 | 0.84 | GRM1 (0.72) | GRM1GRM5HRH1TMEM97TRPV1 | |
| SCHEMBL2891637 | 0.83 | GRM1 (0.77) | GRM1GRM5HRH1TMEM97 | |
| SCHEMBL2888979 | 0.83 | GRM1 (0.70) | GRM1GRM5HRH1TMEM97TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173864-B2 | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor | HOUSE EAR INSTITUTE (US) | 2015-11-03 | — | — | US | claimed |
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | claimed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | claimed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | claimed |
| US-20200085790-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2020-03-19 | — | — | US | disclosed |
| US-20170231958-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9636316-B2 | Baclofen and acamprosate based therapy of neurological disorders | PHARNEXT (FR) | 2017-05-02 | — | — | US | disclosed |
| US-20160000736-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2016-01-07 | — | — | US | disclosed |
| US-9173864-B2 | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor | HOUSE EAR INSTITUTE (US) | 2015-11-03 | — | — | US | disclosed |
| US-9144558-B2 | Baclofen and acamprosate based therapy of neurological disorders | PHARNEXT (FR) | 2015-09-29 | — | — | US | disclosed |
| US-20150038464-A1 | METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2015-02-05 | — | — | US | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038464-A1 | METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION | GRM5, GRM1, GRIK5 | GRM1 2/4885GRM5 1/4885HRH1 707/4885 |
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | GRM1 1/4885GRM5 26/4885HRH1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.